JP2009515183A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009515183A5 JP2009515183A5 JP2008539508A JP2008539508A JP2009515183A5 JP 2009515183 A5 JP2009515183 A5 JP 2009515183A5 JP 2008539508 A JP2008539508 A JP 2008539508A JP 2008539508 A JP2008539508 A JP 2008539508A JP 2009515183 A5 JP2009515183 A5 JP 2009515183A5
- Authority
- JP
- Japan
- Prior art keywords
- protein isoform
- subject
- neurological
- affinity reagent
- abundance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000001708 Protein Isoforms Human genes 0.000 claims 24
- 108010029485 Protein Isoforms Proteins 0.000 claims 24
- 208000012902 Nervous system disease Diseases 0.000 claims 22
- 208000025966 Neurological disease Diseases 0.000 claims 20
- 238000000034 method Methods 0.000 claims 12
- 239000003153 chemical reaction reagent Substances 0.000 claims 11
- 238000012360 testing method Methods 0.000 claims 9
- 210000005013 brain tissue Anatomy 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 238000003745 diagnosis Methods 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 238000004393 prognosis Methods 0.000 claims 4
- 238000012216 screening Methods 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 229960002715 nicotine Drugs 0.000 claims 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 238000002603 single-photon emission computed tomography Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0522667A GB0522667D0 (en) | 2005-11-08 | 2005-11-08 | New protein isoforms and uses thereof |
| US73479905P | 2005-11-09 | 2005-11-09 | |
| PCT/GB2006/050375 WO2007072070A1 (en) | 2005-11-08 | 2006-11-08 | New protein isoforms and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009515183A JP2009515183A (ja) | 2009-04-09 |
| JP2009515183A5 true JP2009515183A5 (enExample) | 2009-12-24 |
Family
ID=37845158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008539508A Pending JP2009515183A (ja) | 2005-11-08 | 2006-11-08 | 新たなタンパク質アイソフォーム及びその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20090311180A1 (enExample) |
| EP (1) | EP1999150A1 (enExample) |
| JP (1) | JP2009515183A (enExample) |
| WO (1) | WO2007072070A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010005387A1 (en) * | 2008-07-10 | 2010-01-14 | Astrazeneca Ab | New method and biomarkers for the diagnosis of multiple sclerosis |
| DE102008054716A1 (de) * | 2008-12-16 | 2010-06-17 | Evonik Degussa Gmbh | Inprozesskontrolle in einem Verfahren zur Herstellung von EPO |
| CA2754072C (en) | 2009-03-02 | 2019-01-15 | Massachusetts Institute Of Technology | Methods and products for in vivo enzyme profiling |
| US8778307B2 (en) | 2009-06-05 | 2014-07-15 | University Of Maryland, College Park | Targeted carriers for drug delivery across the gastrointestinal epithelium |
| JP5190423B2 (ja) * | 2009-08-04 | 2013-04-24 | ホーユー株式会社 | ２次元電気泳動方法 |
| CA3214092A1 (en) | 2011-03-15 | 2012-09-20 | Massachusetts Institute Of Technology | Multiplexed detection with isotope-coded reporters |
| US20140037656A1 (en) * | 2011-04-30 | 2014-02-06 | Mitchell S. Felder | Treatment for Tauopathies |
| EP2714096B1 (en) | 2011-06-03 | 2018-02-28 | Ophidion Inc. | Compositions and methods for transport across the blood brain barrier |
| US9244946B2 (en) | 2012-11-26 | 2016-01-26 | International Business Machines Corporation | Data mining shape based data |
| JP6847660B2 (ja) | 2013-06-07 | 2021-03-24 | マサチューセッツ インスティテュート オブ テクノロジー | リガンドをコードする合成バイオマーカーのアフィニティベースの検出 |
| US11448643B2 (en) | 2016-04-08 | 2022-09-20 | Massachusetts Institute Of Technology | Methods to specifically profile protease activity at lymph nodes |
| WO2017193070A1 (en) | 2016-05-05 | 2017-11-09 | Massachusetts Institute Of Technology | Methods and uses for remotely triggered protease activity measurements |
| AU2018248327B2 (en) | 2017-04-07 | 2024-10-10 | Massachusetts Institute Of Technology | Methods to spatially profile protease activity in tissue and sections |
| WO2020068920A2 (en) | 2018-09-25 | 2020-04-02 | Massachusetts Institute Of Technology | Lung protease nanosensors and uses thereof |
| EP3911753A1 (en) | 2019-01-17 | 2021-11-24 | Massachusetts Institute of Technology | Sensors for detecting and imaging of cancer metastasis |
| RU2734649C1 (ru) * | 2020-02-11 | 2020-10-21 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Пептид, обладающий активностью белка lynx1 (варианты), фармацевтическая композиция для лечения тревожных расстройств и депрессии или коррекции когнитивных нарушений при нейродегенеративных заболеваниях, содержащая указанный пептид, и способ лечения и коррекции указанных нарушений |
| WO2020167167A2 (ru) * | 2019-02-13 | 2020-08-20 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Пептид, обладающий активностью белка lynx1, (варианты), фармацевтическая композиция для лечения тревожных расстройств и депрессии или коррекции когнитивных нарушений при нейродегенеративных заболеваниях, содержащая указанный пептид, и способ лечения и коррекции указанных нарушений |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1114153A2 (en) * | 1998-09-18 | 2001-07-11 | The Rockefeller University | Lynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses therof |
| US20020156009A1 (en) * | 2000-11-02 | 2002-10-24 | Dennis Ballinger | Novel interleukin - 1 Hy2 materials and methods |
| EP1408333A3 (en) * | 2001-10-03 | 2006-10-25 | Pfizer Products Inc. | Diagnosis and treatment of Alzheimer's disease |
| JP4288180B2 (ja) * | 2002-03-29 | 2009-07-01 | 邦雄 高野 | 歯周病リスクの判定方法 |
| US20060078890A1 (en) * | 2004-10-08 | 2006-04-13 | Ole Isacson | Methods for identifying parkinson's disease therapeutics |
-
2006
- 2006-11-08 WO PCT/GB2006/050375 patent/WO2007072070A1/en not_active Ceased
- 2006-11-08 US US12/085,076 patent/US20090311180A1/en not_active Abandoned
- 2006-11-08 JP JP2008539508A patent/JP2009515183A/ja active Pending
- 2006-11-08 EP EP06808739A patent/EP1999150A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Serrano-Pozo et al. | A phenotypic change but not proliferation underlies glial responses in Alzheimer disease | |
| Bowser et al. | Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations | |
| JP2009515183A5 (enExample) | ||
| Reichmann | Premotor diagnosis of Parkinson’s disease | |
| Yang et al. | Temporal MRI characterization, neurobiochemical and neurobehavioral changes in a mouse repetitive concussive head injury model | |
| Lafrenaye et al. | Circulating GFAP and Iba-1 levels are associated with pathophysiological sequelae in the thalamus in a pig model of mild TBI | |
| Alber et al. | Retina pathology as a target for biomarkers for Alzheimer's disease: Current status, ophthalmopathological background, challenges, and future directions | |
| Irimia et al. | Cerebral microhemorrhages due to traumatic brain injury and their effects on the aging human brain | |
| CN106461645A (zh) | 外伤性脑损伤和神经退行性生物标记物、方法和系统 | |
| US20170307640A1 (en) | Methods, kits and devices for detecting bii-spectrin, and breakdown products thereof, as biomarkers for the diagnosis of neural injury | |
| Barron et al. | Assessment of neuroinflammation in a mouse model of obesity and β-amyloidosis using PET | |
| Dede et al. | Rapid eye movement sleep without atonia constitutes increased risk for neurodegenerative disorders | |
| Albayram et al. | Traumatic Brain Injury-related voiding dysfunction in mice is caused by damage to rostral pathways, altering inputs to the reflex pathways | |
| Zengil et al. | Evaluation of serum zonulin and occludin levels in bipolar disorder | |
| TW202002976A (zh) | 治療含有高神經絲輕鏈含量之個體之方法 | |
| Schmidt et al. | Autonomic dysfunction in patients with progressive supranuclear palsy | |
| Dios et al. | Class I and II histone deacetylase expression is not altered in human amyotrophic lateral sclerosis: Neuropathological and positron emission tomography molecular neuroimaging evidence | |
| Song et al. | Blood–brain barrier impairment is functionally correlated with clinical severity in patients of multiple system atrophy | |
| Pakdaman et al. | Efficacy and safety of MLC601 in the treatment of mild cognitive impairment: a pilot, randomized, double-blind, placebo-controlled study | |
| Tullo et al. | Female mice exhibit resistance to disease progression despite early pathology in a transgenic mouse model inoculated with alpha-synuclein fibrils | |
| JP2009506301A5 (enExample) | ||
| Chan | Early diagnosis, monitoring, and treatment of optic neuritis | |
| WO2006003414A2 (en) | Biomarkers of alzheimer's disease | |
| WO2010005077A1 (ja) | パーキンソン病の疾患関連たんぱく質およびその使用 | |
| Gonçalves et al. | Past appendectomy may be related to early cognitive dysfunction in Parkinson’s disease |